Michael P. Bailey - 19 Jan 2023 Form 4 Insider Report for AVEO PHARMACEUTICALS, INC.

Reporting relationship: President & CEO, Director
Issuer ticker: N/A
Reported as of: 19 Jan 2023
Net transaction value: -$4,997,505
SEC form: 4
Accepted by SEC: 19 Jan 2023, 16:11:51 UTC
Prior SEC filing: 22 Dec 2022
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Danielle V. Holland, attorney in fact

Key filing fact

Michael P. Bailey filed Form 4 for AVEO PHARMACEUTICALS, INC. on 19 Jan 2023.

Key facts

This page summarizes Michael P. Bailey's Form 4 filing for AVEO PHARMACEUTICALS, INC..
13 reported transactions and 12 derivative rows are listed below.
Accepted by SEC: 19 Jan 2023, 16:11.

Change

Previous filing in this sequence was filed on 22 Dec 2022.
Current net transaction value: -$4,997,505.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVEO transaction

Common Stock

Disposed to Issuer

Transaction value: $4,997,505
Shares: -333,167
Change %: -100%
Price: $15.00
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -3,249
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,249
Exercise price: $77.20
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -11,999
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,999
Exercise price: $25.10
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -7,499
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,499
Exercise price: $17.70
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -90,000
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $8.40
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -46,000
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,000
Exercise price: $10.80
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -75,366
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,366
Exercise price: $6.00
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -99,999
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 99,999
Exercise price: $30.80
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -16,750
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,750
Exercise price: $15.70
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -93,500
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,500
Exercise price: $6.20
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -35,302
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,302
Exercise price: $5.60
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -275,100
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 275,100
Exercise price: $9.12
Footnotes: F2

AVEO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -625,192
Change %: -100%
Price
Shares after: 0
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 625,192
Exercise price: $3.67
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Michael P. Bailey is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.

Footnote F2

This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

SEC remarks

On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration").